I går aftes så jeg en ganske udmærket dokumentar om firmaet Novo Nordisk. Måske dette var en idé at skrive om, kombineret med historien om Insulin?
lidt baggrund:
http://www.netpatient.dk/iddm_insulin_historie.htmog lidt tekst:
The founding of Novo Nordisk
Novo Nordisk's history spans more than 70 years. The story begins in 1922 when a Danish couple, August and Marie Krogh, travelled to America. August Krogh was a professor at the University of Copenhagen who had received the Nobel Prize in physiology. His wife, Marie Krogh, was a doctor and researcher in metabolic diseases. Marie also suffered from late-onset (Type 2) diabetes.
While in America the Kroghs heard of two Canadian researchers, Frederick Banting and Charles Best, who were treating people with diabetes with an insulin extract from bovine pancreases. The Kroghs were very interested in this treatment because of Marie's diabetes, and they ultimately were granted permission to produce insulin in Denmark.
On their return to Denmark, Krogh and Dr H C Hagedorn, a specialist in the regulation of blood sugar, decided that some extensive research was required. They called on the Danish pharmacist August Kongsted who offered to pay for the research and help start production. On 21 December 1922 the two men succeeded in extracting a small quantity of insulin from a bovine pancreas and the first patients were treated in March 1923. In spring 1923 they founded Nordisk Insulinlaboratorium (Nordisk).
In 1923 the engineer Harald Pedersen joined Nordisk to build the machines used for insulin production. His brother, Thorvald Pedersen, was later recruited to analyse the chemical processes during insulin production. However, Thorvald Pedersen did not get on with Hagedorn, and in 1924 Hagedorn fired him. Out of loyalty to his brother Harald resigned and the two brothers set up on their own. By 1924 they too were successfully producing insulin and in 1925 the brothers sent a letter to Danish pharmacists informing them that Insulin Novo and the newly developed Novo syringe were now on sale. The brothers named their company Novo Terapeutisk Laboratorium (Novo). There were now two firms in Denmark that were to develop into the world's leading manufacturers of insulin.
Over the next 65 years both companies rapidly expanded. Both established large research units and competed furiously to be the first on the market with new products for the treatment of diabetes. Nordisk and Novo also both began to diversify by developing other products. Novo became the world's largest producer of industrial enzymes, and Nordisk developed drugs for the treatment of haemophilia and growth disorders.
In January 1989 Novo and Nordisk decided to join forces. Having competed with each other for more than 60 years, the two companies could now concentrate their combined forces on developing new products for treating diabetes and on conquering world markets. The new company was called Novo Nordisk A/S.
In early 1999 it was decided that Novo Nordisk would de-merge into two main businesses: Healthcare and Enzymes. The de-merger enables the two businesses to increase their operational freedom and focus on what they do best. On 14 November 2000 Novo Nordisk and Novozymes began operating as two separately listed companies. And so the story continues...
Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.
1923 Nordisk Insulinlaboratorium founded.
1925 Novo Terapeutisk Laboratorium founded.
1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital.
1938 Novo founds Hvidøre Diabetes Sanatorium.
1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used for bating leather before tanning.
1946 Nordisk develops Isophane insulin (NPH), a neutral insulin with prolonged action.
1947 Penicillin Novo is launched – Novo’s first product to be manufactured through fermentation – is launched.
1953 Lente® – a long-acting insulin-zinc suspension – is launched.
1963 Alcalase® – Novo’s first detergent enzyme produced by fermentation – is launched.
1973 Nordisk Gentofte markets Nanormon® growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
1973 Monocomponent (MC) insulin is introduced – the purest insulin available.
1974 Novo’s B shares are quoted on the Copenhagen Stock Exchange.
1977 Trisequens® – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed.
1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
1982 Human Monocomponent insulin is launched – the world’s first insulin preparation identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin.
1984 Kliogest® – continuous combined oral HRT for post-menopausal women – is launched.
1985 NovoPen® – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
1987 Novo starts production of human insulin with the help of genetically engineered yeast cells.
1988 Nordisk Gentofte markets Norditropin® genetically engineered human growth hormone.
1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become the world’s leading producer of insulin.
1989 NovoLet® – the world’s first prefilled insulin syringe – is marketed.
1992 Seroxat® – a drug for the treatment of depression – is marketed.
1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
1994 Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report.
1996 NovoSeven® – for the treatment of haemophilia patients with inhibitor reaction – is launched.
1998 NovoNorm®/Prandin®, a new oral treatment for Type 2 diabetes, is launched in the US and a number of European countries.
1998 Activelle® – the first low-dose continuous combined oral HRT for post-menopausal women – is introduced.
1999 Novo Nordisk publishes its first social report.
1999 Innovo®, the world’s first insulin doser with a built-in electronic memory, is launched in Europe.
1999 NovoRapid® (NovoLog® in the US) – the first rapid-acting insulin analogue – is marketed.
1999 Norditropin® SimpleXx® – the world’s first liquid growth hormone in a dedicated pen system – is launched.
2000 Novofem™, a low-dose sequential combined oral HRT, is marketed in Germany. Two years later it is launched in several other European countries.
2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
2001 InnoLet® – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
2001 InDuo® – the world’s first combined blood glucose monitor and insulin injection system – is introduced.
2001 FlexPen®, a new prefilled pen with high safety and simple design, is marketed in Switzerland and Denmark.
2001 Novo Nordisk acquires controlling interest in the Brazilian pharmaceutical company Biobrás.
2002 NovoMix® 30 – a dual-release insulin analogue – is launched.